Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE AGM THE 2021 FIRST A SHAREHOLDERS' CLASS MEETING AND THE 2021 FIRST H SHAREHOLDERS' CLASS MEETING ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS RETIREMENT OF DIRECTORS CHANGE IN THE COMPOSITION OF BOARD COMMITTEES DISTRIBUTION OF FINAL DIVIDEND AND CLOSURE PERIOD OF REGISTER OF MEMBERS OF H SHARES(H SHARES)

06/11/2021 | 10:30am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE AGM

THE 2021 FIRST A SHAREHOLDERS' CLASS MEETING AND

THE 2021 FIRST H SHAREHOLDERS' CLASS MEETING

ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

RETIREMENT OF DIRECTORS

CHANGE IN THE COMPOSITION OF BOARD COMMITTEES

DISTRIBUTION OF FINAL DIVIDEND

AND

CLOSURE PERIOD OF REGISTER OF MEMBERS OF H SHARES

The annual general meeting (the ''AGM''), the 2021 first class meeting of holders of A shares of the Company (the ''A Shareholders' Class Meeting'') and the 2021 first class meeting of holders of H shares of the Company (the ''H Shareholders' Class Meeting'') (collectively, the ''Meetings'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') were convened at Le Meridien Shanghai Minhang, No. 3199 Cao Bao Road, Shanghai, the PRC on Friday, 11 June 2021 at 1:00 p.m..

References are made to the notice of the AGM, the notice of H Shareholders' Class Meeting and the circular (the ''Circular'') of the Company, all dated 12 May 2021. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the Meetings, (i) the total number of the issued shares of the Company (the ''Shares'') was 2,562,898,545 Shares, comprising 2,010,958,045 A Shares and 551,940,500 H Shares;

  1. holders of 2,562,898,545 Shares (or by authorized proxies) were entitled to attend and vote on the resolutions proposed at the AGM; and (iii) holders of 2,010,958,045 A Shares (or by authorized proxies) and 551,940,500 H Shares (or by authorized proxies) were entitled to attend and vote on the resolutions at the A Shareholders' Class Meeting and H Shareholders' Class Meeting, respectively. There were no Shares entitling the Shareholders to attend and vote only against the resolutions at the Meetings.

- 1 -

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, according to the relevant laws, regulations and the Articles, the following Shareholders, and their respective associates have a material interest in the relevant resolutions regarding the proposed adoption of the 2021 Restricted Share Incentive Scheme and the Proposed Grant, the Management Measures for the Appraisal System, and the mandate to be granted to the Board to deal with matters pertaining to the 2021 Restricted Share Incentive Scheme, were required to and had abstained from voting on such resolutions at the relevant Meetings:

  1. Mr. Wu Yifang, who is a Director and interested in 718,900 A Shares and 342,000 H Shares, representing approximately 0.04% of the total issued share capital of the Company as at the Latest Practicable Date and is a proposed Participant under the 2021 Restricted Share Incentive Scheme, is required to abstain from voting on resolutions no. 16, 17 and 18 at the AGM and resolutions no. 3, 4 and 5 at the A Shareholders' Class Meeting, the H Shareholders' Class Meeting, respectively;
  2. Mr. Liu Qiang, Mr. Wang Kexin, Mr. Li Dongming, Ms. Guan Xiaohui, Mr. Wen Deyong, Ms. Feng Rongli, Mr. Li Shengli, Mr. Wang Yao, Mr. Liu Yi, Ms. Su Li, Mr. Zhou Yong and Mr. Kong Deli, who are connected persons of the Company and interested in an aggregate of 509,000 A Shares, representing approximately 0.02% of the total issued share capital of the Company as at the Latest Practicable Date, and are proposed Participants under the 2021 Restricted Share Incentive Scheme, are required to and will abstain from voting on resolutions no. 16, 17 and 18 at the AGM and resolutions no. 3, 4 and 5 at the A Shareholders' Class Meeting, respectively; and
  3. the other proposed Participants, who are interested in an aggregate of 115,250 A Shares and 700 H Shares, representing approximately 0.01% of the total issued share capital of the Company as at the Latest Practicable Date, are required to and will abstain from voting on resolutions no. 16, 17 and 18 at the AGM and resolutions no. 3, 4 and 5 at the A Shareholders' Class Meeting, H Shareholders' Class Meeting, respectively.

Fosun High Tech and Fosun International, the controlling shareholders of the Company, Mr. Wu Yifang, Mr. Chen Qiyu, Mr. Yao Fang, Mr. Chen Yuqing, Ms. Mei Jingping, Mr. Wang Yao and other corporate or individual shareholders, who has interest in the transactions contemplated under the resolution in relation to the estimated ongoing related party transactions or 2021 of the Group were required to and had abstained from voting at the AGM for such resolution. Mr. Chen Qiyu and Mr. Yao Fang were required and had abstained abstained from voting at the AGM on resolutions in relation to the appraisal results and appraisal program. To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, save as disclosed above, no other Shareholder, none of the connected persons of the Company, the Shareholders and their respective associates has any material interest in the resolutions proposed at the AGM, the A Shareholders' Class Meeting or the H Shareholders' Class Meeting and is required to abstain from voting at the AGM, the A Shareholders' Class Meeting or the H Shareholders' Class Meeting.

- 2 -

ATTENDANCE AT THE MEETINGS

  1. Attendance at the AGM:
    Set out below are the details of the Shareholders and authorized proxies present at the AGM:

Number of Shareholders and authorized proxies

309

Including:

Number of A Shareholders

308

Number of H Shareholders

1

Total number of Shares carrying voting rights (shares)

1,175,530,453

Including:

Total number of Shares carrying voting rights held by

1,044,339,941

A Shareholders

Total number of Shares carrying voting rights held by

131,190,512

H Shareholders

Percentage of the total number of Shares (%)

45.8672

Including:

Number of A Shares as a percentage of the number

40.7484

of Shares (%)

Number of H Shares as a percentage of the number

5.1188

of Shares (%)

(II) Attendance at the A Shareholders' Class Meeting:

Set out below are the details of the A Shareholders and authorized proxies present at the A Shareholders' Class Meeting:

Number of A Shareholders and authorized proxies

308

Total number of A Shares carrying voting rights (shares)

1,044,339,941

Number of A Shares as a percentage of the total number of A Shares of

51.9325

the Company (%)

(III) Attendance at the H Shareholders' Class Meeting:

Set out below are the details of the H Shareholders and authorized proxies present at the H Shareholders' Class Meeting:

Number of H Shareholders and authorized proxies

1

Total number of H Shares carrying voting rights (shares)

131,167,013

Number of H Shares as a percentage of the total number of H Shares of

23.7647

the Company (%)

The Meetings were convened in compliance with the requirements of the Company Law and the Articles of Association, and was chaired by Mr. Wu Yifang, chairman of the Company.

- 3 -

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, Shareholder's representatives and members of the supervisory committee of the Company acted as the scrutineers for the vote-counting at each of the Meetings.

POLL RESULTS OF THE RESOLUTIONS PROPOSEDS AT THE MEETINGS

  1. Poll results of the AGM:
    All resolutions at the AGM were voted by poll. The poll results in respect of the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS

Number of valid votes

For

Against

Abstain

1.

To consider and approve the annual

1,174,651,303

242,450

636,700

report of the Group for the year 2020.

(99.9252%)

(0.0206%)

(0.0542%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.

To consider and approve the work report

1,174,830,703

39,550

660,200

of the Board for the year 2020.

(99.9405%)

(0.0034%)

(0.0561%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

3.

To consider and approve the work report

1,174,834,003

36,250

660,200

of the Supervisory Committee for the

(99.9408%)

(0.0031%)

(0.0561%)

year 2020.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

4.

To consider and approve the final

1,174,608,903

259,650

661,900

accounts report of the Group for the year

(99.9216%)

(0.0221%)

(0.0563%)

2020.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

5.

To consider and approve the profit

1,174,569,737

901,616

59,100

distribution proposal of the Company for

(99.9183%)

(0.0767%)

(0.0050%)

the year 2020.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

- 4 -

ORDINARY RESOLUTIONS

Number of valid votes

For

Against

Abstain

6.

To consider and approve the re-

1,175,252,516

217,337

60,600

appointment of Ernst & Young Hua

(99.9764%)

(0.0185%)

(0.0051%)

Ming LLP as the PRC financial report

and internal control report auditors of the

Company for the year 2021 and re-

appointment of Ernst & Young as

international financial report auditors of

the Company for the year 2021 and the

passing of remuneration packages for the

PRC and international auditors for the

year 2020.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

7.

To consider and approve the appraisal

1,175,273,603

167,850

89,000

results and remunerations of executive

(99.9782%)

(0.0143%)

(0.0075%)

Directors for 2020.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

8.

To consider and approve the estimates of

236,514,413

34,350

167,500

ongoing related party transactions of the

(99.9147%)

(0.0145%)

(0.0708%)

Group for 2021.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

9.

To consider and approve the renewed and

1,162,878,230

12,573,623

78,600

additional entrusted loan/borrowing quota

(98.9237%)

(1.0696%)

(0.0067%)

of the Group.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

10.

To consider and approve the additional

1,175,421,803

39,550

69,100

credit applications of the Company.

(99.9908%)

(0.0034%)

(0.0058%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

- 5 -

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 11 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 June 2021 14:29:03 UTC.


© Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
More news
Financials
Sales 2021 40 257 M 6 231 M 6 231 M
Net income 2021 4 253 M 658 M 658 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 48,3x
Yield 2021 0,64%
Capitalization 197 B 30 553 M 30 531 M
EV / Sales 2021 5,30x
EV / Sales 2022 4,69x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 81,88 CNY
Average target price 57,08 CNY
Spread / Average Target -30,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman